



6th Immune Effector Cell Therapies in Multiple Myeloma Workshop

Boston, MA • March 28-29, 2025

Friday, March 28, 2025

7:00 - 8:00	BREAKFAST	
8:00 - 8:10	INTRODUCTION AND WELCOME	
8:10 - 8:45	PLENARY TALK	Crystal Mackall
8:45 - 10:00	SESSION 1: CLINICAL UPDATES ON CAR T CELLS <i>Chairs: Pieter Sonneveld and Yi Lin</i>	
8:45 - 9:00	Ide-cel and Cilta-cel: latest data and ongoing trials	Thomas Martin
9:00 - 9:10	Real world data for BCMA CAR T cells	Surbhi Sidana
9:10 - 9:20	Novel autologous BCMA CAR T cells: latest data and ongoing trials	Matthew Frigault
9:20 - 9:30	Update on GPRC5D CAR T cells	Maung Myo Htut
9:30 - 10:00	Discussion	Session faculty + Francesca Gay
10:00 - 10:30	BREAK	
10:30 - 11:50	SESSION 2: CLINICAL UPDATES ON BISPECIFIC ABS/TCE'S <i>Chairs: Jesus San Miguel and Sundar Jagannath</i>	
10:30 - 10:40	Teclistamab monotherapy and combinations: Latest data and ongoing trials	Maria-Victoria Mateos
10:40 - 10:50	Elranatamab monotherapy and combinations: Latest data and ongoing trials	Mohamad Mohty
10:50 - 11:00	Talquetamab monotherapy and combinations: Latest data and ongoing trials	Ajai Chari
11:00 - 11:10	Update on linvoseltamab, ABBV-383 and cevostamab	Joshua Richter
11:10 - 11:20	Real world data for bispecific antibodies	Susan Bal
11:20 - 11:50	Discussion	Session faculty + Marc Raab

11:50 - 1:00

LUNCH

1:00 - 2:30

SESSION 3: PRACTICAL CONSIDERATIONS FOR IMMUNE THERAPY

Chairs: Saad Usmani and Hermann Einsele

1:00 - 1:10	What's the best time to give CAR T Cells - frontline, 2nd line, or beyond?	Paula Rodriguez-Otero
1:10 - 1:20	How to manage relapse after CAR T cells or Bispecifics	Krina Patel
1:20 - 1:30	Using CAR T cells and bispecific Abs for AL amyloidosis	Eyal Lebel
1:30 - 1:40	CAR T cell and Bi-specific in SMM	Omar Nadeem
1:40 - 1:50	How to utilize belantamab mafodotin in a T cell-engaging world	Suzanne Trudel
1:50 - 2:00	Sustaining an academic CAR T Cell program	Alvaro Urbano-Ispizua
2:00 - 2:30	Discussion	Session faculty + Vania Hungria

2:30 - 3:00

BREAK

3:00 - 4:20

SESSION 4: NOVEL APPROACHES IN THE CLINIC

Chairs: Philippe Moreau and Noopur Raje

3:00 - 3:10	Allogeneic/off-the-shelf CAR T cells - still worth pursuing?	Bhagirathbhai Dholaria
3:10 - 3:20	Dual antigen targeting with CAR T cells and trispecific antibodies	Jesus Berdeja
3:20 - 3:30	CAR-NK cells and NK-targeting bispecifics	Joaquin Martinez Lopez
3:30 - 3:40	Targeting ROR2 and SLAMF7 with CAR T cells	Michael Hudecek
3:40 - 3:50	Combining CAR T cells and bispecific Abs	Adam Cohen
3:50 - 4:20	Discussion	Session faculty + Eric Smith

4:20 - 5:30

SESSION 5: MANAGING TOXICITIES OF T CELL ENGAGING THERAPIES

Chairs: Simon Harrison and Monique Minnema

4:20 - 4:30	Should we be using prophylactic tocilizumab?	Jonathan Kaufman
4:30 - 4:40	Mitigating talquetamab-related oral and skin toxicities	Leo Rasche
4:40 - 4:50	Immune effector cell-associated enterocolitis	Noffar Bar
4:50 - 5:00	Stem cell rescue for persistent cytopenias post-CAR T cells	Carolina Schinke
5:00 - 5:30	Discussion	Session faculty + Binod Dhakal

5:30 - 5:45

CONCLUSION

Saturday, March 29, 2025

7:00 - 8:00

BREAKFAST

8:00 - 8:05

WELCOME

8:05 - 9:25

SESSION 6: CORRELATES OF RESPONSE AND RESISTANCE

Chairs: Niccolo Bolli and Kwee Yong

8:05 - 8:15	T cell factors impacting response to CAR T cell therapy	Marcela Maus
8:15 - 8:25	Microenvironment factors impacting response to CAR T cell therapy	Samir Parekh
8:25 - 8:35	Novel resistance mechanisms to bispecific Ab therapy	Nizar Bahlis
8:35 - 8:45	Immune profiling for response prediction	Bruno Paiva
8:45 - 8:55	Tumor genomics and response to immune therapy	Paola Neri
8:55 - 9:05	Circulating tumor DNA to predict response/resistance	Johannes Waldschmidt
9:05 - 9:25	Discussion	Session faculty + Mehmet Samur

9:25 - 10:45

SESSION 7: STRATEGIES TO IMPROVE IMMUNE EFFECTOR CELL THERAPIES

Chairs: Amrita Krishnan and Madhav Dhodapkar

9:25 - 9:35	CellMOD's to enhance safety and efficacy of CAR T cells and bispecific Abs	Marta Larrayoz
9:35 - 9:45	CAR-enhancers for myeloma	Mohammad Rashidian
9:45 - 9:55	In vivo T cell engineering	Adi Barzel
9:55 - 10:05	Overcoming T cell exhaustion and tumor resistance	Marco Ruella
10:05 - 10:15	Combine T cell engaging therapy with vaccination	David Avigan
10:15 - 10:45	Discussion	Session faculty + Niels van de Donk

10:45 - 11:00

BREAK

11:00 - 12:00

SESSION 8: KEY QUESTIONS IN IMMUNE THERAPY

Chairs: Sonja Zweegman and Hearn Cho

11:00 - 11:10	Can we cure myeloma with "Total Immune Therapy"?	Sagar Lonial
11:10 - 11:20	Is MRD a viable endpoint for immune effector cell therapy trials?	Nikhil Munshi
11:20 - 11:30	Which target should we hit first: BCMA or GPRC5D (or Both)?	Sham Mailankody
11:30 - 12:00	Discussion	Session faculty + Cyrille Touzeau

12:00 - 1:00

LUNCH

1:00 - 2:00

**WORKSHOP ON SECONDARY MALIGNANCIES
AND NON-RELAPSE MORTALITY**

Chairs: Kenneth Anderson and Shaji Kumar

1:00 - 1:10

Non-relapse mortality after CAR T cells

David Cordas dos Santos

1:10 - 1:20

Non-relapse mortality after Bispecific Abs

Meera Mohan

1:20 - 1:30

Myeloid and lymphoid malignancies after
immune effector cell therapy

Adam Sperling

1:30 - 2:00

Discussion

Session faculty + Ajay Nooka

2:00 - 2:15

CONCLUSION AND WRAP-UP

Thank you to our sponsors

TITANIUM



PLATINUM



SILVER

